VPC
APRE icon

Vestal Point Capital’s Aprea Therapeutics APRE Stock Holding History

Vestal Point Capital’s Portfolio APRE Stock Details APRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$267K Buy
+350,000
New +$275K 0.01% 90

Other funds holding APRE

ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SRL
Scientech Research LLC Jersey City, New Jersey $120M AUM 73.62% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Vestal Point Capital's APRE Position: Q1 2026 in Review

Vestal Point Capital opened a new position in Aprea Therapeutics (APRE) in Q1 2026: 350,000 shares worth $267K. The stake represents 0.01% of the portfolio and ranks #90 among its holdings.

22 funds tracked by Wall St. Rank hold APRE as of Q1 2026.

  • Vestal Point Capital held 350,000 shares of Aprea Therapeutics worth $267K as of Q1 2026.
  • Aprea Therapeutics was a new Vestal Point Capital position in Q1 2026.
  • Aprea Therapeutics made up 0.01% of Vestal Point Capital's portfolio in Q1 2026, its #90 holding.
  • 22 funds tracked by Wall St. Rank held Aprea Therapeutics as of Q1 2026.

Based on Vestal Point Capital's 13F filing for Q1 2026, filed 15 May 2026.